Added ibrutinib in first-line CLL treatment

(4:22)

Ianalumab add-on therapy in CLL patients receiving ibrutinib

(1:47)

The SHINE Study: Adding Ibrutinib to BR - Blood Cancers Video Library

(3:)

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

(6:7)

Additional Insights: Management of Ibrutinib in CLL

(5:19)

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

(3:11)

Dr. van den Brink Discusses Adding Ibrutinib to R-CHOP in NHL

(58)

Ibrutinib treatment and its associated risk factors

(1:56)

Case 1: Ibrutinib +/- CD20 Antibodies in CLL

(4:55)

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

(1:29)

Dr. Tendler on the Mechanism of Action of Ibrutinib

(2:5)

Ibrutinib resistance-mechanisms and options in CLL

(29:14)

Ibrutinib Therapy in Chronic Lymphocytic Leukemia

(6:32)

Case 3: Managing Ibrutinib-Associated Toxicities in CLL

(3:58)

Treatment Strategies With Ibrutinib in CLL

(3:22)

CLL: Chemotherapy and Ibrutinib based regimens

(25:38)

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

(8:51)

Adding umbralisib to ibrutinib produced responses in MCL, CLL

(37)

The characteristics and mode of action of ibrutinib for CLL

(3:46)

Phase Ib trial of ianalumab plus ibrutinib for CLL

(4:8)